GlassScriptPhysician profile
Kyle W Barnum
NPI 1689192494
$2,425.15
in general payments reported to CMS, 2019-2025
34 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $585 · 2023: $614 · 2024: $645 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $749.46 | 2021-2025 | |
| Lilly USA, LLC | $164.62 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Supernus Pharmaceuticals, INC. | $129.21 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $117.60 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi Pasteur INC. | $115.74 | 2022-2023 | |
| Pfizer INC. | $100.37 | 2021-2025 | |
| Axsome Therapeutics, INC. | $94.47 | 2022-2024 | Auvelity |
| Astellas Pharma US INC | $86.46 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $73.65 | 2022-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Abbott Laboratories | $66.93 | 2021-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $64.81 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $62.47 | 2022-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.49 | 2021-2023 | Synjardy, Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.82 | 2021-2025 | Xifaxan |
| Cranial Technologies, INC | $52.41 | 2022-2025 | Doc Band |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $42.27 | 2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $40.02 | 2021-2024 | Trintellix |
| Lundbeck LLC | $37.09 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $35.19 | 2022-2023 | |
| Novo Nordisk INC | $32.84 | 2021-2024 | Wegovy |
| Amarin Pharma, INC. | $30.69 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.69 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.76 | 2025 | Caplyta |
| Amgen INC. | $20.67 | 2025 | Otezla, Repatha |
| Ironshore Pharmaceuticals INC. | $17.69 | 2023 | Jornay Pm |
| Corcept Therapeutics | $17.24 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $17.20 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.83 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $15.64 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $15.38 | 2022 | |
| Esperion Therapeutics, INC. | $14.65 | 2021 | |
| Organon LLC | $12.19 | 2025 | Nexplanon |
| Biohaven Pharmaceuticals, INC. | $11.37 | 2021 | |
| Neos Therapeutics, LP | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Barnum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.